What we're reading, December 15, 2015: call centers overwhelmed by last-minute rush for health insurance enrollment; AstraZeneca exploring deal with Acerta Pharma; and despite near universal health insurance coverage in Massachusetts, patients have access issues.
Affordable Care Act call centers were overwhelmed by the large numbers of consumers trying to enroll in healthcare coverage that would be effective January 1, 2016, before the deadline at midnight on Tuesday, according to USA Today. There were so many calls that some people were asked to leave their names and contact information. If they called back after the deadline, they would still be able to have their coverage start on January 1, according to CMS.
AstraZeneca is looking to get in on the deal frenzy happening in healthcare. The United Kingdom drugmaker is considering a deal with Acerta Pharma, which would give AstraZeneca acalabrutinib, reported Bloomberg Business. The experimental drug is a rival of Imbruvica, and shows promise against an incurable form of leukemia, as well as auto-immune diseases. The 2 companies are still in talks, but the deal could cost more than $5 billion, according to The Wall Street Journal.
Finally, a study has found that while Massachusetts has near universal health insurance coverage, access to care remains a struggle, according to MassLive.com. More than one-fifth of residents have trouble getting a timely appointment. More than one-third of respondents said they had visited the emergency department in the last year, and of those, 38% said it was for something that could have been treated by a non-emergency doctor. Close to 60% said they went to the emergency department because they couldn’t get an appointment with a doctor in a timely manner.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Racial Differences in CA-125 Levels Tied to Ovarian Cancer Treatment Delays
April 17th 2025Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at diagnosis, resulting in delayed chemotherapy initiation and highlighting the need for more inclusive guidelines.
Read More
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
April 15th 2025Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Read More